春立醫療(01858.HK)年度營收同比增長9.63%至9.4億元
格隆匯 3 月 29日丨春立醫療(01858.HK)發佈年度業績公吿,截至2020年12月31日止年度,集團的營業收入同比增長9.63%至約人民幣9.377億元,主要是由於關節假體產品銷量的增長及銷售網絡的擴張所致。
集團的毛利同比增長14.71%至約人民幣6.808億元,主要是由於陶瓷關節假體產品、XN膝關節假體產品等主流關節假體產品(屬於相對單價較高的中、高端產品)在行業內增長迅速所致。毛利率由截至2019年的69.38%上升到截至2020年的72.60%,主要是由於採購議價能力加強,導致原材料毛坯等價格下降及公司量產導致固定成本相對下降所致。集團的淨利潤同比增加19.68%至約人民幣2.834億元,淨利潤的增長主要來自於集團收入的增長和毛利率的改善。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.